Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described bicyclic tetrahydrothiazepine derivatives acting as diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
Novel pyrimidinyl and triazinyl sulfonamide derivatives acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-like) antagonists have been reported in an F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented phosphorylpurinone compounds acting as Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described new 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described imidazo[4,5-b]pyridine and pyrazolo[1,5-a]pyrimidine derivatives acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of juvenile idiopathic arthritis, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche, Inc. have described fluorescent probes acting as monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for diagnostic imaging of MAGL.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described indazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and eye disorders.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified haloindole macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s and Alzheimer’s diseases.
An F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. patent describes indole derivatives acting as EGFR L858R mutant, T790M/L858R double mutant, T790M/L858R/C797S triple mutant and/or L858R/C797S double mutant allosteric inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
